CID 11021937

Base Information Edit

Chemical Name:CID 11021937
CAS No.:19262-68-1
Molecular Formula:C14H19 N O2 . Cl H
Molecular Weight:269.771
Hs Code.:2933399090
Mol file:19262-68-1.mol

Synonyms:

This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.

Chemical Property of CID 11021937 Edit

Chemical Property:

Vapor Pressure:0.000199mmHg at 25°C
Melting Point:218-220°C
Refractive Index:1.523
Boiling Point:327.6°Cat760mmHg
Flash Point:152°C
PSA：38.33000
Density:g/cm³
LogP:3.21610
Storage Temp.:Controlled Substance, -20°C Freezer
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:3
Rotatable Bond Count:4
Exact Mass:269.1182566
Heavy Atom Count:18
Complexity:249

Purity/Quality:

Safty Information:

Pictogram(s):
Hazard Codes:Xn
Statements: 22

MSDS Files:

Useful:

Canonical SMILES:COC(=O)C(C1CCCC[NH2+]1)C2=CC=CC=C2.[Cl-]
Isomeric SMILES:COC(=O)[C@@H]([C@H]1CCCC[NH2+]1)C2=CC=CC=C2.[Cl-]
Description Dexmethylphenidate, the pharmacologically effective enantiomer of d,l-methyl phenidate (Ritalin?) was developed as an improved treatment for attention deficit hyperactivity disorder (ADHD) in children. Dexmethylphenidate acts via the inhibition of reuptake of dopamine (by binding to dopamine transporter) and nor-adrenaline. It is thought to block dopamine and noradrenaline reuptake into the presynaptic neuron and increase neurotmnsmitter release into the extraneuronal space. Dexmethytphenidate, at half the usual dose of racemic methylphenidate, improved the symptoms of attention deficit hyperactivity disorder to a similar extent to methylphenidate in both home and school settings (SNAP-ADHD scores) at 3 h post dosing. Moreover, some studies showed that dexmethylphenidate has a statistically significant longer duration of action than the racemic form as measured by a behavioral scale at 6 h post dosing compared to placebo. In patients with ADHD, plasma dexmethylphenidate concentrations increased rapidly, reaching a maximum in the fasted state at approximately l-l.5 h post-dose. The mean plasma half-life for dexmethylphenidate is approximately 2.2 h. Dexmethylphenidate is metabolized to d-α-phenyl-piperidine acetic acid, its main urinary metabolite which has negligible pharmacological activity. In vitro studies showed that dexmethylphenidate did not inhibit cytochrome P450 isozymes. Dexmethylphenidate was well tolerated; the most commonly reported adverse events (abdominal pain, headache, anorexia, insomnia) were mild in severity and consistent with those known to be associated with agents containing methylphenidate. Current labeling states that dexmethylphenidate should be administered twice daily with an interval of at least 4 hours between doses. Stimulant medications have been used for over sixty years and remain, until now, the first line pharmacological therapy for children with ADHD, demonstrating effectiveness in roughly 70% of patients.
Uses Controlled substance. CNS stimulant. More potent enantiomer Controlled substance. CNS stimulant. The more potent isomers of Methylphenidate. The threo enantomers have shown that the pharmacological activity residues predominantly in the d-threo enantiomer.

Technology Process of CID 11021937

There total 71 articles about CID 11021937 which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 100.0%